Abbott (NYSE:ABT) faces a proposed class action lawsuit related to alleged tracking tools used with its FreeStyle Libre ...

Some people are facing delays in filling prescriptions for the glucose sensor. Abbott expects to resolve the problem soon.

Abbott launched an over-the-counter continuous glucose monitoring system, Lingo, for adults not on insulin -- the second such ...

The US Food and Drug Administration (FDA) has tagged Abbott’s recent recall of its faulty FreeStyle Libre 3 sensors as Class ...

DexCom's revised FY24 sales guidance in the Q2 earnings call led to a $18bn valuation reset. Read why I think DXCM stock is a ...

Abbott Laboratories' (NYSE: ABT) business has been a bit of a roller coaster. The pandemic disrupted its medical device ...

Tandem Diabetes Care (Nasdaq:TNDM) announced today that it received clearance for the use of rapid-acting insulin with its ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The FDA designated Abbott's recall of FreeStyle Libre 3 sensors as the most serious, class I type due to the risk for ...

ABBOTT PARK, Ill. - Abbott has issued a recall for certain FreeStyle Libre 3 sensors due to a risk for inaccurate high glucose readings.

Thursday, Abbott Laboratories ABT said it is recalling some FreeStyle Libre 3 sensors after finding that a small number of FreeStyle Libre 3 sensors may provide incorrect high glucose readings.

Piper Sandler initiated coverage on Abbott Laboratories (NYSE: ABT) with an "overweight" rating and a price target of $131 ...

Abbott's wearable FreeStyle Libre 3 device – which is billed as the smallest and thinnest real-time CGM system available – sends glucose readings every minute directly to the user's smartphone ...